Progress of drug resistance mechanism of poly adenosine diphosphate ribose polymerase inhibitors and the combined medication in patients with ovarian cancer / 肿瘤研究与临床
Cancer Research and Clinic
; (6): 473-477, 2022.
Article
in Zh
| WPRIM
| ID: wpr-958876
Responsible library:
WPRO
ABSTRACT
Ovarian cancer seriously threats women's health. The emergence of poly adenosine diphosphate ribose polymerase inhibitor (PARPi) has broken the barrier for ovarian cancer treatment. PARPi has been widely used and along with it comes the problem of drug resistance. Fully understanding the drug resistance mechanism of PARPi is expected to be an important way to reverse PARPi resistance. The combination of PARPi and other drugs for ovarian cancer may expand the benefits of patients using PARPi. This article reviews the drug resistance mechanism of PARPi and combined medication.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Cancer Research and Clinic
Year:
2022
Type:
Article